等待開盤 11-05 09:30:00 美东时间
+3.480
+1.40%
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从50美元升至51美元;HC Wainwright & Co.:上调伊诺维奥制药评级至"买入",目标价5美元
11-03 18:20
11月3日,渤健(BIIB)收跌1.82%,报249.01美元,成交额2.93亿美元,市值367.92亿美元。 行情数据 • 开盘价:253.81美元 • 最高...
11-03 05:39
Supernus Pharmaceuticals 2026财年第三季度财报电话会议涵盖了18%的营收增长、更强劲的产品销售、上调的独立业绩指引以及与 Indivior 尚待完成的合并案。
10-29 21:45
Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter. The company posted adjusted earnings of $2.62 per share, beating market estimates of $1.98 per share. The company’s sales came in at $2.804 billion versus expectations of $2.632 billion. Biogen narrowed...
10-29 19:38
今日重点评级关注:BTIG:维持Cullinan Therapeutics"买入"评级,目标价从40美元升至41美元;Rosenblatt:维持SK海力士"买入"评级,目标价从320美元升至400美元
10-29 12:30
在第三季度营收增长11%、且在Apellis的支持下增长型产品组合营收激增49%后,渤健上调了其2026年非GAAP每股收益指引的下限。
10-29 00:02
Biogen raised the lower end of its 2026 non-GAAP EPS guidance after Q3 revenue rose 11% and growth-portfolio revenue surged 49%, supported by Apellis.
10-29 00:01
Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.
10-28 23:27
渤健(BIIB.US)10月28日盘前发布第三季度业绩:总营收28.04亿美元,同比增长11%,固定汇率情景下增长10%,高于市场预期的26.3亿至26.8亿美元
10-28 18:58